Extrapulmonary pneumocystosis in an antiretroviral therapy-naïve, HIV-positive patient

Makoto Hasegawa, Yuji Ito, Yasuhiro Osugi, Masahiro Hashimoto, Nanako Hashimoto, Kunio Yano

研究成果: ジャーナルへの寄稿学術論文査読

3 被引用数 (Scopus)


Pneumocystis jirovecii is a common opportunistic fungal pathogen that commonly affects immunocompromised individuals and can cause P. jirovecii pneumonia. Extrapulmonary P. jirovecii infections are extremely rare. Herein, we present a case of an HIV-positive, antiretroviral therapy–naïve patient who had extrapulmonary pneumocystosis (EPC). He presented with complaints of decreased appetite, abdominal fullness, and weight loss. Computed tomography (CT) revealed multiple low-attenuation masses in the spleen, liver, and both adrenal glands but no pulmonary involvement. A core-needle biopsy of a splenic lesion confirmed the diagnosis of EPC. The patient was initiated on intravenous trimethoprim-sulfamethoxazole (TMP-SMX) and CT–guided percutaneous catheter drainage of the splenic lesion was performed. Intravenous TMP-SMX therapy was completed in 3 weeks and intravenous pentamidine (250 mg daily) therapy was commenced. Pentamidine was completed after 3 weeks, and antiretroviral treatment (ART) was initiated with dolutegravir 50 mg and Descovy HT (emtricitabine [200 mg] and tenofovir alafenamide fumarate [25 mg]). After starting ART, the patient's clinical condition improved, and the abscesses gradually reduced. TMP-SMX is commonly used to treat EPC; however, there is no standard method of treatment. ART may become the key to EPC treatment in individuals with HIV infection.

ジャーナルInternational Journal of Infectious Diseases
出版ステータス出版済み - 07-2022

All Science Journal Classification (ASJC) codes

  • 微生物学(医療)
  • 感染症


「Extrapulmonary pneumocystosis in an antiretroviral therapy-naïve, HIV-positive patient」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。